Azelnidipine

Azelnidipine (INN; marketed under the brand name CalBlock — カルブロック) is a dihydropyridine calcium channel blocker. Azelnidipine is L and T calcium channel blocker. It is sold in Japan by Daiichi-Sankyo pharmaceuticals, Inc. Unlike nicardipine, it has a gradual onset and has a long-lasting hypotensive effect, with little increase in heart rate. Drug Controller General Of India (DCGI) has approved the use of azelnipine in India. It is launched under the brand name Azusa (ajanta pharma ltd.)[1] In 2020, JB Chemicals launched it in India under the brand name Azovas[2]

Azelnidipine
Clinical data
Trade namesCalBlock,AZUSA
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.162.151
Chemical and physical data
FormulaC33H34N4O6
Molar mass582.657 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

References

  1. Oizumi K, Nishino H, Koike H, Sada T, Miyamoto M, Kimura T (September 1989). "Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker". Jpn. J. Pharmacol. 51 (1): 57–64. doi:10.1254/jjp.51.57. PMID 2810942.Scholar search
  2. "Azovas Azelnidipine-Physician Information Page". Medical Dialogues. 1 July 2020. Retrieved 1 July 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.